Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MABp1 PK Study in Healthy Volunteers
NCT03047317Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bermekimab in hidradenitis suppurativa (HS) and atopic dermatitis (AD), sponsored by Janssen Pharmaceutical. Primary endpoints: Peak Plasma Concentration at 2 weeks, Time to Peak Plasma Concentration at 2 weeks and 2 more. Started Feb 2017; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03047317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047317.